Our website uses cookies. By continuing to browse our site you are agreeing to our Cookie Policy.
Back To Top
In The News

Moderna partners with Swiss firm Lonza to produce potential coronavirus vaccine

May 1, 2020
Moderna, the Cambridge drug company whose experimental vaccine for the novel coronavirus was first in the United States to make it to clinical trials, has partnered with Swiss drug maker Lonza to manufacture up to 1 billion doses a year of the potential vaccine ― should it be approved by regulators ― the companies announced Friday. Read the full article By Jeremy C. Fox, Globe Correspondent on www.bostonglobe.com

Related Stories

In The News

Emerson Ventures Invests in First Resonance

September 28, 2023
Emerson has made a strategic investment through Emerson Ventures, its corporate venture capital arm, in First Resonance, a Los Angeles-based start-up transforming manufacturing with its ION Factory Operating System (OS).
Read More
In The News

NECI Named On CRISPR Therapeutics ISPE FOYA Award, Third FOYA Contribution In Four Years

December 20, 2022
NECI contributed to the CRISPR facility's success by supplying its automation and control systems. This marks the third time in four years that NECI has contributed to a FOYA award-winning facility.
Read More
In The News

Emerson Title Sponsor and Keynote Presenter at Fugitive Emissions Summit Americas 2022

September 7, 2022
This coming September 28 to 29, 2022, the Fugitive Emissions Summit Americas will bring together a community of end users, EPCs, distributors, manufacturers, and suppliers dedicated to improving workplace practices, in efforts to reduce environmental damage caused by industrial emissions.
Read More